Chengdu Easton Biopharmaceuticals Co (SHSE:688513) EPS (Basic): ¥1.58 (TTM As of Mar. 2026)

What is Chengdu Easton Biopharmaceuticals Co EPS (Basic)?

Chengdu Easton Biopharmaceuticals Co SHSE:688513 -4.52% 95 EPS (Basic) is ¥1.58 as of Mar. 2026. GuruFocus rates SHSE:688513 with a GF Score™ of 95/100 and a GF Value™ of ¥47.90 (Fairly Valued). The stock has 4 warning signs investors should review.

Chengdu Easton Biopharmaceuticals Co's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ¥0.29. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1.58.

Chengdu Easton Biopharmaceuticals Co's EPS (Diluted) for the three months ended in Mar. 2026 was ¥0.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1.58.

Chengdu Easton Biopharmaceuticals Co's EPS without NRI for the three months ended in Mar. 2026 was ¥0.26. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1.49.

During the past 12 months, Chengdu Easton Biopharmaceuticals Co's average EPS without NRIGrowth Rate was 21.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 8.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Chengdu Easton Biopharmaceuticals Co's highest 3-Year average EPS without NRI Growth Rate was 51.50% per year. The lowest was -9.40% per year. And the median was 8.80% per year.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Chengdu Easton Biopharmaceuticals Co EPS (Basic) Related Terms

Chengdu Easton Biopharmaceuticals Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Chengdu Easton Biopharmaceuticals Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Easton Biopharmaceuticals Co EPS (Basic) Chart

Chengdu Easton Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

1.32

1.40

1.28

1.36

1.63

Chengdu Easton Biopharmaceuticals Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															0.34	0.43	0.48	0.38	0.29

95GF Score

Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Chengdu Easton Biopharmaceuticals Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Chengdu Easton Biopharmaceuticals Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(284.059	-	0)	/	174.270
	=	1.63

Chengdu Easton Biopharmaceuticals Co's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(50.831	-	0)	/	175.279
	=	0.29

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.58

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of ¥1.58 mean?

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a EPS (Basic) of ¥1.58 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors.

Is Chengdu Easton Biopharmaceuticals Co's EPS (Basic) too high?

Chengdu Easton Biopharmaceuticals Co's current EPS (Basic) is ¥1.58. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Chengdu Easton Biopharmaceuticals Co's EPS (Basic) compare to VRTX and REGN?

Chengdu Easton Biopharmaceuticals Co's EPS (Basic) of ¥1.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. Chengdu Easton Biopharmaceuticals Co's current EPS (Basic) is ¥1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥47.90, compared to a current price of ¥52.61 — trading 9.8% above its estimated fair value. The current EPS (Basic) is ¥1.58. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current EPS (Basic) is ¥1.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued. The current stock price of ¥52.61 is trading 9.8% above its estimated GF Value™ of ¥47.90. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.

Key valuation signals for SHSE:688513:

EPS (Basic): ¥1.58
GF Value™: ¥47.90 vs. price of ¥52.61 (9.8% above fair value)
GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Easton Biopharmaceuticals Co Business Description

Industry Healthcare Biotechnology

Comparable Companies SHSE:600866 SZSE:300294 SHSE:688177 SZSE:002030 SHSE:688068 SZSE:301080 SZSE:301047 SHSE:688253 SHSE:603229 SHSE:605116 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731

Website http://www.eastonpharma.cn

Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.

95GF Score

Get the complete analysis for SHSE:688513

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥52.61

Price

¥47.90

GF Value

View SHSE:688513 Analysis

See EPS (Basic) data for all stocks →